.png){kind=icon}
.png){kind=icon}
Return
Immunohistochemical Assay Variability and HER2-low Breast Cancer Detection: A Laboratory Comparison in the Netherlands
.png){kind=icon}
OA
AI
Z
E
X
H
P
N
C
DOI：10.1016/j.labinv.2026.106136.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
HER2-low breast cancer (BC) has gained clinical relevance due to the efficacy of trastuzumab deruxtecan (T-DXd). However, variability in detecting low HER2 expression may affect patient eligibility. This nationwide study in the Netherlands evaluated the variability in HER2 immunohistochemistry (IHC) assays at low expression levels and compared this to the reported HER2-low rates across pathology laboratories.
Keywords:
breast cancer
HER2-low
immunohistochemistry
interlaboratory variability
antibody clone
level of detection
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.2
Papers:
5.4K
Citations:
1.1W
Organization
Cited Papers